Clinical Trial: A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer

U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07766018) titled 'A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer' on Aug. 10.

Brief Summary: This is a multicenter, open-label, Phase 2 bridging study to evaluate the efficacy and safety of elacestrant in Japanese post-menopausal women and men with estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer with estrogen receptor 1 gene mutation (ESR1-mut) whose disease has relapsed or progressed on at least 1 and no more than 2 prior lines of endocrine therapy for metastatic breast cancer, which must have included cyclin-dependent kinase ...